Cell Line-Derived Xenograft (CDX) Models

Cell line derived xenograft models are generated by implanting established human cancer cell lines into immunodeficient hosts. They remain the most widely used and most cost-effective platform for preclinical efficacy testing, and they occupy a defensible position in the development workflow: rapid triage, mechanism confirmation, and dose-schedule optimization, ahead of the slower and more resource-intensive patient-derived platforms.

Altogen Labs maintains a library of validated xenograft models spanning brain, breast, colon, gastric, kidney, liver, leukemia, lung, lymphoma, melanoma, ovarian, pancreatic, prostate, and sarcoma indications, together with bladder, cervical, and head and neck models. Each model is characterized for growth kinetics and implantation parameters in-house, so that cohort sizing and study duration are set from observed behavior rather than estimated. Company scientists have published antitumor efficacy data generated in these models.

Why CDX remains the first in vivo platform

The case for CDX rests on experimental cleanliness. Authenticated cell lines can be genetically manipulated, expanded at scale, and implanted into large matched cohorts with comparatively little biological noise. That permits interpretable efficacy, pharmacodynamic, and tolerability readouts on timelines impractical for patient-derived or humanized systems. Canonical lines are anchored to decades of mechanistic literature and to public molecular annotation resources, so model selection can be made against documented pathway status rather than empirically.

Historical criticism of cell line predictivity has been refined rather than upheld. A substantial part of the apparent failure reflects study design, including small panels, mismatched histologies, and absent molecular stratification, rather than intrinsic failure of the model class. Used as a mechanism and triage platform rather than as a surrogate for clinical outcome, CDX answers target dependency, comparative efficacy, and proof of mechanism questions reliably.

For model selection support or a costed study, request a quote.

Study design

Subcutaneous flank implantation is the standard configuration. Tumor-bearing animals are randomized once tumors reach a defined volume, with randomization stratified by baseline tumor size so treatment arms begin from comparable distributions. Cohort size is set by power calculation against the expected effect size and the observed variance of the specific model rather than by convention, which matters because variance differs substantially between lines.

Primary endpoints are tumor volume, tumor growth inhibition, and survival. Response classification, tumor growth delay, and time to endpoint analyses are applied where the treatment effect is expected to be cytostatic rather than cytoreductive, since a growth inhibition value alone can obscure a durable delay. Tolerability is followed through body weight and protocol-defined clinical observations. Mixed effects modeling is appropriate for longitudinal tumor growth data and Kaplan-Meier analysis for survival endpoints, and the analysis method is pre-specified rather than chosen after the data are seen.

Beyond the subcutaneous flank

Orthotopic and disseminated CDX variants extend the platform to tissue tropism, metastatic colonization, and site-specific therapy without sacrificing the operational advantages of a cell line based system. Reporter-tagged lines, most commonly luciferase expressing, permit longitudinal bioluminescent monitoring where caliper measurement is not possible, and can be generated through reporter stable cell line development.

Applied examples

Dose-schedule optimization. A compound showing activity at a single dose level is tested across three schedules at matched total exposure, establishing whether continuous or intermittent administration produces greater tumor growth inhibition before the schedule is fixed for later studies.

Target-stratified comparison. The same agent is evaluated in two lines differing in the status of the target pathway, so that activity can be attributed to target engagement rather than to general cytotoxicity.

Pharmacodynamic confirmation. A satellite cohort is dosed and harvested at defined timepoints for protein-level pathway analysis, so that target modulation in tumor tissue is demonstrated alongside the growth endpoint rather than assumed.

Model selection and authentication

Lines are selected against the target dependency under investigation, the molecular context in which the agent is expected to act, and the histology of the intended clinical indication. Short tandem repeat profiling confirms identity and detects cross-contamination, and contamination control is applied routinely. Where a suitable line is not available, stable cell line development can generate a model expressing the required target or reporter.

Recognized limitations and when to escalate

The limitations of CDX are well documented and define its proper use. Established lines undergo clonal drift in culture, lack human stroma and immune compartments, and have limited population-level predictive value for clinical response. Where the question requires donor heterogeneity or preserved stroma, PDX is the appropriate escalation. Where it requires an immune compartment, syngeneic or humanized platforms are. Altogen Labs will say when a CDX study cannot answer the question being asked rather than run it anyway.

All procedures are conducted under active IACUC protocols, with humane endpoints and refinement measures defined per model. GLP standards are applied where a study is formally designated as GLP.

Send compound, indication, and target details, or request a quote.